4.6 Review

Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries

期刊

LIFE-BASEL
卷 11, 期 6, 页码 -

出版社

MDPI
DOI: 10.3390/life11060528

关键词

antimicrobials; antimicrobial stewardship programs; antimicrobial resistance; healthcare-associated infections; COVID-19; lower- and middle-income countries; misinformation; patient initiatives; surgical site infections; vaccines

向作者/读者索取更多资源

Antimicrobial resistance is a global concern with initiatives focusing on improving antibiotic use, strengthening antimicrobial stewardship programs, enhancing healthcare facility surveys, and intensifying public health education efforts. Furthermore, new quality indicators need to be developed for monitoring medication use in ambulatory care settings.
Antimicrobial resistance (AMR) is a high priority across countries as it increases morbidity, mortality and costs. Concerns with AMR have resulted in multiple initiatives internationally, nationally and regionally to enhance appropriate antibiotic utilization across sectors to reduce AMR, with the overuse of antibiotics exacerbated by the COVID-19 pandemic. Effectively tackling AMR is crucial for all countries. Principally a narrative review of ongoing activities across sectors was undertaken to improve antimicrobial use and address issues with vaccines including COVID-19. Point prevalence surveys have been successful in hospitals to identify areas for quality improvement programs, principally centering on antimicrobial stewardship programs. These include reducing prolonged antibiotic use to prevent surgical site infections. Multiple activities centering on education have been successful in reducing inappropriate prescribing and dispensing of antimicrobials in ambulatory care for essentially viral infections such as acute respiratory infections. It is imperative to develop new quality indicators for ambulatory care given current concerns, and instigate programs with clear public health messaging to reduce misinformation, essential for pandemics. Regular access to effective treatments is needed to reduce resistance to treatments for HIV, malaria and tuberculosis. Key stakeholder groups can instigate multiple initiatives to reduce AMR. These need to be followed up.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据